The voice of people

with MS in Europe

MS Therapies

 

 

Treating MS – an online guide for good practice in managing multiple sclerosis

 

 “Mutual learning by spreading good practice from national to European level.”

 

We are the European Multiple Sclerosis Platform (EMSP) and this is the motto behind our successful development as a membership driven umbrella organisation with more than 25 years of experience.

 

The most recent example for this approach is the interactive multimedia tool “Treating MS”, launched at our 2015 Annual Conference 2015 held in May, in Warsaw.

 

Click on the image below to launch the application. 

 

  

 

 

Concept

 

With its original title “MS Behandeln”, “Treating MS” was developed by our German member organisation - DMSG - together with one of their regional branches, AMSEL.

 

“Treating MS” is part of an impressive list of multimedia tools in the German language - from an incursion in the history of MS to an online training platform on MS cognition, from a guided tour through a virtual MS clinic to the online training programme eTrain MS.

 

EMSP, DMSG and AMSEL subsequently worked together to adapt the project for the English language.

 

“Treating MS” is designed as a guide on approved MS therapies in Europe, as well as an online training platform meant to help those living with MS and act as their caregiver.

 

 

Acknowledgement

 

EMSP extends its gratitude to DMSG and AMSEL for their professional support and the very timely manner in which they have helped make this project available beyond German speaking countries.

 

 

Call to Members

 

EMSP is inviting all our member organisations to share good practice in similar ways. EMSP stands ready to offer support for translation and adaptation for a wider European audience.

Lemtrada 12 mg - approved as treatment for multiple sclerosis

 

The European Commission has granted marketing authorization for Lemtrada (alemtuzumab), indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS), Genzyme has announced in a press release.

 

"Multiple sclerosis necessitates a highly individualized treatment approach, and the increasing diversity of options is good news," said Hans-Peter Hartung, Professor and Chairman of the Department of Neurology at Heinrich-Heine-University in Duesseldorf, Germany. "The Lemtrada clinical trial data support its potential to meaningfully address disability in active RRMS patients".